The Nigeria Center for Disease Control (NCDC) has said that the new COVID-19 medication, Dexamethasone has not been affirmed for use in the treatment of patients with the viral sickness in Nigeria.
The medication, which researchers in the United Kingdom have hailed as a significant discovery, is a generally utilized low-portion steroid which has been found to extensively diminish the danger of patients kicking the bucket from COVID-19.
The NCDC in a progression of Tweets posted on Tuesday night, June 16 said it knows about the medication, anyway the medication has not yet been affirmed for use in Nigeria.
“The Nigeria Center for Disease Control (NCDC) knows about late results from a UK-Government subsidized clinical preliminary for COVID-19. The outcomes bolster the utilization of Dexamethasone as a potential treatment to decrease the danger of death among COVID-19 patients, who require oxygen or mechanical ventilation.
If it’s not too much trouble note that the Government of Nigeria has not approved or affirmed any treatment for COVID-19. Also, the utilization of Dexamethasone for COVID-19 treatment has not been approved by WHO.
We know about continuous clinical preliminaries led by researchers in the UK and will work with our sister organizations to assess this developing information on the utilization of Dexamethasone. We will educate the overall population on results following logical survey and approval.” the NCDC tweet read